retatrutide pen injector (30/40/60mg) Retatrutide injection hi-res stock photography
Description
Dual- and triple-receptor agonists also offer the potential for the treatment of obesity (3941)
It is currently being evaluated in phase II and phase III clinical trials, primarily for obesity
SPF, specific pathogen-free
The clinic focuses on tailoring treatment plans to individual health profiles, rather than relying on standardised weight loss approaches
GLP-1 Receptor Agonist Market Size and Trends Forecast: 2026 - 2033 GLP-1 receptor agonist market is estimated to be valued at USD 31.71 Bn in 2026 and is expected to reach USD 72.33 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2026 to 2033
Retatrutide is drawing interest because it extends that concept further by adding glucagon receptor activity to GLP-1 and GIP
